The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban
Abstract
This open‐label study evaluated apixaban pharmacokinetics, pharmacodynamics, and safety in subjects with mild, moderate, or severe renal impairment and in healthy subjects following a single 10‐mg oral dose. The primary analysis determined the relationship between apixaban AUC∞ and 24‐hour creatinine clearance (CL cr) as a measure of renal function. The relationships between 24‐hour CL cr and iohexol clearance, estimated CL cr (Cockcroft‐Gault equation), and estimated glomerular filtration rate (modification of diet in renal disease [MDRD] equation) were also assessed. Secondary objectives included assessment of safety and tolerability as well as international normalized ratio (INR) and anti–factor Xa activity as pharmacodynamic endpoints. The regression analysis showed that decreasing renal function resulted in modestly increased apixaban exposure (AUC∞ increased by 44% in severe impairment with a 24‐hour CL cr of 15 mL/min, compared with subjects with normal renal function), but it did not affect C max or the direct relationship between apixaban plasma concentration and anti–factor Xa activity or INR. The assessment of renal function measured by iohexol clearance, Cockcroft‐Gault, and MDRD was consistent with that determined by 24‐hour CL cr. Apixaban was well tolerated in this study. These results suggest that dose adjustment of apixaban is not required on the basis of renal function alone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
Apixaban in patients with atrial fibrillation
Connolly, S. J., Eikelboom, J., Joyner, C., Diener, H.-C., Hart, R., Golitsyn, S., Flaker, G., Avezum, A., Hohnloser, S. H., Diaz, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1007432 · Cited by 2,483
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Masiukiewicz, U., Pak, R., Thompson, J., Raskob, G. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302507 · Cited by 2,324
Apixaban for Extended Treatment of Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Porcari, A., Raskob, G. E., & Weitz, J. I. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1207541 · Cited by 1,366
Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement
Lassen, M. R., Gallus, A., Raskob, G. E., Pineo, G., Chen, D., & Ramirez, L. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006885 · Cited by 775
Cited by
Horlocker, T. T., Vandermeuelen, E., Kopp, S. L., Gogarten, W., Leffert, L. R., & Benzon, H. T. (2018) · Regional Anesthesia and Pain Medicine · doi:10.1097/aap.0000000000000763 · Cited by 932
Doherty, J. U., Gluckman, T. J., Hucker, W. J., Januzzi, J. L., Ortel, T. L., Saxonhouse, S. J., & Spinler, S. A. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.024 · Cited by 441
Tomaselli, G. F., Mahaffey, K. W., Cuker, A., Dobesh, P. P., Doherty, J. U., Eikelboom, J. W., Florido, R., Gluckman, T. J., Hucker, W. J., Mehran, R., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.04.053 · Cited by 397
Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review
Byon, W., Garonzik, S., Boyd, R. A., & Frost, C. E. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00775-z · Cited by 348
Self-citationWang, X., Tirucherai, G., Marbury, T. C., Wang, J., Chang, M., Zhang, D., Song, Y., Pursley, J., Boyd, R. A., & Frost, C. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.628 · Cited by 286
Self-citation
Metadata
- Authors
- Chang, M., Yu, Z., Shenker, A., Wang, J., Pursley, J., Byon, W., Boyd, R. A., LaCreta, F., & Frost, C. E.
- Venue
- The Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2015-12-04
- Volume
- 56
- Issue
- 5
- Pages
- 637-645
- ISSN
- 0021-9754 (ISSN-L)
- 0091-2700
- 1552-4604
- OpenAlex
- W2116532362
- Cited by
- 171
- References
- 7
- FWCI
- 14.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban. https://app.cochat.ai/papers/10.1002/jcph.633
- The paper
- Chang, M., Yu, Z., Shenker, A., Wang, J., Pursley, J., Byon, W., Boyd, R. A., LaCreta, F., & Frost, C. E. (2016). Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.633
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.